Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
JERSEY CITY, N.J., Aug. 31, 2016 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences:
- The Baird Global Healthcare Conference at the New York Palace Hotel on Wednesday, September 7, 2016 at 4:20 p.m. ET.
- The 23rd Annual NewsMakers in the Biotech Industry Investment Conference at the Millennium Broadway in New York on Friday, September 9, 2016 at 9:30 a.m. ET.
- The Aegis Growth Conference at the Wynn Las Vegas on Thursday, September 22, 2016 at 9:00 a.m. PT.
Live webcasts of the presentations will be available on the investors section of the Company's website: www.SCYNEXIS.com. Replays of each presentation will be available approximately two hours after each event and will be available for two weeks following the presentations.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of serious and life-threatening invasive fungal infections. For more information, visit www.SCYNEXIS.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212.203.4433 [email protected]
